Oculocutaneous albinism

Oculocutaneous albinism (OCA) is a group of inherited disorders characterized by a reduction or complete absence of melanin pigment in the skin, hair, and eyes. The condition results from defects in the synthesis or distribution of melanin, the pigment responsible for coloring these tissues. Several subtypes exist, including OCA1 (caused by mutations in the TYR gene), OCA2 (OPA gene, also known as P gene), OCA3 (TYRP1 gene), OCA4 (SLC45A2 gene), OCA5, OCA6 (SLC24A5 gene), OCA7 (LRMDA gene), and OCA8 (DCT gene), each associated with different genetic defects but sharing overlapping clinical features. The hallmark features of OCA include hypopigmentation of the skin and hair ranging from complete absence of pigment to mild reduction, and characteristic ocular findings. Eye involvement is a defining feature across all subtypes and includes reduced iris pigmentation, nystagmus (involuntary eye movements), foveal hypoplasia (underdevelopment of the central retina), reduced visual acuity, photophobia (light sensitivity), and misrouting of the optic nerve fibers at the chiasm. The degree of pigment reduction varies considerably both between and within subtypes, with some individuals showing near-normal skin and hair pigmentation but still having significant ocular manifestations. There is currently no cure for oculocutaneous albinism. Management is supportive and multidisciplinary, focusing on protection of the skin from ultraviolet radiation damage through sunscreen use, protective clothing, and regular dermatologic surveillance for skin cancers, to which affected individuals are highly susceptible. Ophthalmologic care includes correction of refractive errors, management of strabismus, and use of low-vision aids. Tinted lenses or filters may help with photophobia. Genetic counseling is recommended for affected individuals and their families. Research into pharmacological approaches, including nitisinone for OCA1B, is ongoing but no disease-modifying therapies are currently approved for routine clinical use.

Common questions about Oculocutaneous albinism